You searched for "networking"
In conversation with Andrena McElvanney (President, MCLOSA)
22 September 2022
|
EYE - Cornea
We spoke to Andrena about MCLOSA's annual meeting this November, key developments in cornea and external eye disease, and plans for the association’s 30th anniversary. Andrena McElvanney (top, second from right) and the OSI council members. The Medical Contact Lens...
Eyes on Tomorrow podcast: “Desert Island Discs for ophthalmologists”
What happens when an ophthalmologist and optometrist get chatting in a pub, over a couple of pints of Guinness, about how they could create something educational and entertaining for ophthalmologists and optometrists? The answer is the Eyes on Tomorrow podcast....My Top Five: A foundation doctor’s top five misconceptions about ophthalmology
4 December 2023
| Carina Mouritsen Luxhoj
|
EYE - General
Choosing a specialty is challenging. As a foundation doctor, it often feels as if this choice is based solely on fleeting experiences. Compared to other specialties, there is relatively little exposure to ophthalmology during either medical school or foundation years....
Blind Aberdeenshire man stresses importance of volunteering
As we mark Volunteers’ Week, RNIB Scotland is proud to tell the story of one of our longstanding volunteers and community members, Bruce Christie (59). Bruce, who is from Westhill, was diagnosed with keratoconus in 2003, along with other minor...Breakthroughs in the genetics of angle-closure glaucoma
1 April 2017
| Sancy Low, Paul J Foster (Prof)
|
EYE - Glaucoma
Angle closure glaucoma (ACG) is not widely known to be a familial condition, yet the recent explosion of genetic data and large scale genome wide investigations have confirmed at least 13 genetic loci associated with ACG [1], and provided some...
End of an era: completing training. Tips for survival, fellowship applications and how to CCT
1 February 2019
| Tafadzwa Young-Zvandasara
|
EYE - General
Tafadzwa Young-Zvandasara shares the things he wishes he had paid more attention to when approaching the end of training. It is the end of an era, you are now ready to move on. Training has been filled with a structured...
Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments
1 February 2017
| Manoj V Parulekar
|
EYE - Oncology
Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...
Principles of management
Whatever section of pathology is to blame and wherever it strikes, the aim of treatment is always the same. Find the cause if you can. Establish the effects of the cause. Halt the pathological process if you can. Reverse its...Stem cell therapy for Parkinson’s disease: researching for an effective cure
1 December 2015
| Romina Vuono
|
EYE - Neuro-ophthalmology
Neurodegenerative diseases are characterised by the chronic and progressive loss of neurons, which in turn results in loss of cognitive and physical functions. The World Health Organization has estimated that the disability-adjusted life years lost from neurological disease was about...
Patient and public participation shapes biomedical research and access priorities in eye health
1 December 2014
| Rod McNeil
|
EYE - General
Patients, clinicians and clinician-scientists play a valuable role in shaping the future of vision research. Limited funding demands targeted research initiatives that ultimately will shape health policy and practice to secure progress in improving patient outcomes in eye health. This...
Corporate M&A pace gathers momentum
1 October 2019
| Rod McNeil
|
EYE - General
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...
